Which Treatment Fits Your Weight Management Goals?
Compare Mounjaro and Wegovy: Mechanism Differences
When you compare Mounjaro and Wegovy, the fundamental difference lies in their molecular mechanisms. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone, reducing appetite and promoting satiety after smaller meals. Mounjaro utilises tirzepatide, a dual-action medication targeting both GIP and GLP-1 receptors, offering a broader hormonal approach to weight management. Both prescription-only medicines work alongside a reduced-calorie diet and increased physical activity to support sustainable weight loss.
This Wegovy vs Mounjaro comparison reveals that whilst both treatments influence appetite regulation, their receptor targeting differs significantly. Wegovy's singular GLP-1 focus provides a well-established pathway with extensive clinical data, whilst Mounjaro's dual mechanism represents newer therapeutic innovation. Your prescriber can evaluate which approach aligns better with your medical history, current medications, and treatment goals. Both options require careful dose escalation and ongoing clinical monitoring throughout your weight management journey.
Wegovy vs Mounjaro Pricing and Value Analysis
EverydayMeds offers transparent pricing when you compare Mounjaro and Wegovy costs across treatment phases. Wegovy pricing ranges from £79.99 for the 0.25mg starter dose to £209.99 for the 2.4mg maintenance dose, with new customers applying code FIRST40 at checkout for optimal value. Our Getting Started bundles, like the Intro Duo at £169.99, provide seamless dose progression without multiple orders. Returning customers benefit from code DOSE25 for continued savings throughout their treatment journey.
Mounjaro pricing follows a different structure with six available doses from 2.5mg to 15mg, accommodating various tolerance levels and therapeutic requirements. Both medications qualify for our next-day cold-chain delivery service, ensuring temperature integrity from our GPhC-registered pharmacy (#9012878) to your door. Bundle options provide convenience benefits including Reliable Supply continuity and reduced ordering frequency, particularly valuable for maintenance phase patients. Investment in either treatment represents a commitment to medically-supervised weight management with ongoing prescriber support.
Clinical Evidence: Compare Mounjaro and Wegovy Trial Results
Wegovy's clinical foundation rests on the comprehensive STEP trial programme, where participants achieved approximately 15% average weight loss at 68 weeks when combined with lifestyle interventions. The landmark STEP 1 study (Wilding et al., NEJM, 2021) demonstrated sustained weight reduction versus placebo, whilst STEP 5 confirmed maintenance over two years. Recent SELECT trial data revealed a 20% reduction in major cardiovascular events, expanding Wegovy's therapeutic profile beyond weight management alone.
Mounjaro's clinical evidence stems from the SURMOUNT trial series, showing significant weight reduction outcomes with tirzepatide's dual mechanism approach. However, directly comparing trial percentages between Wegovy vs Mounjaro proves challenging due to different study designs, participant populations, and endpoint measurements. Both treatments demonstrated efficacy when participants adhered to reduced-calorie diets and increased physical activity protocols, reinforcing that medication alone cannot may support results without lifestyle commitment.
How Wegovy Works in Your Weight Management Journey
Wegovy operates as a GLP-1 receptor agonist, essentially mimicking incretin hormones that naturally regulate appetite and food intake. When you inject semaglutide weekly, it activates specific brain receptors responsible for hunger signals, reducing your desire to eat and increasing feelings of fullness after smaller portions. The medication also slows gastric emptying, meaning food remains in your stomach longer, contributing to prolonged satiety between meals. This mechanism helps address the biological challenges that make sustainable weight loss difficult through diet and exercise alone. Unlike stimulant-based weight loss medications, Wegovy works with your body's existing hormonal pathways rather than artificially boosting metabolism. The treatment requires consistent weekly administration to maintain therapeutic levels and optimal appetite regulation throughout your weight management programme.
Streamlined Ordering Process for Both Treatments
EverydayMeds simplifies access to both medications through our comprehensive online platform designed for UK patients. Your journey begins with a thorough 3-minute clinical assessment covering medical history, current medications, weight management goals, and any contraindications that might influence treatment selection. Our qualified prescribers review applications within standard 3 working days, though express 24-hour review is available for urgent requirements. Once approved, both Wegovy and Mounjaro dispatch via next-day delivery using specialised cold-chain packaging to maintain temperature integrity during transport. Our GPhC-registered pharmacy (#9012878) ensures all medications meet UK quality standards and regulatory requirements. Ongoing support includes dose adjustment guidance, side effect monitoring, and treatment optimisation throughout your weight management journey.
Storage and Practical Considerations
Storage requirements present a key practical difference when you compare Mounjaro and Wegovy for daily life integration. Wegovy offers superior travel flexibility, remaining stable at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration, compared to Mounjaro's 21-day limit. Both medications require initial refrigerated storage at 2-8°C before first use, using similar FlexTouch pen delivery systems for weekly injections. Wegovy's dose escalation follows a structured 5-step protocol over 16 weeks, whilst Mounjaro offers 6 available strengths allowing more granular dose adjustments based on tolerance and efficacy. The injection technique remains consistent between treatments, with comprehensive instructions provided alongside your first delivery. Both medications require careful disposal of used pens through appropriate sharps containers, available free from most UK pharmacies and diabetes centres.
Dual-Mechanism vs Single-Target: Compare Mounjaro and Wegovy Approaches
The Wegovy vs Mounjaro decision often centres on therapeutic approach preferences and individual response patterns. Wegovy's established GLP-1 pathway provides predictable outcomes backed by extensive real-world usage data, making it suitable for patients preferring proven mechanisms. Its cardiovascular benefits, demonstrated in the SELECT trial, add therapeutic value beyond weight management for patients with existing heart disease risk factors. The medication's dosing simplicity and storage advantages appeal to patients prioritising convenience alongside clinical efficacy.
Mounjaro's dual GIP/GLP-1 mechanism may appeal to patients who haven't achieved optimal results with single-target approaches or those seeking innovative treatment pathways. The additional receptor targeting theoretically provides broader metabolic effects, though individual responses vary significantly. Some patients find Mounjaro's flexible dosing options better accommodate their tolerance levels and lifestyle requirements. Both treatments require similar injection frequency and lifestyle commitment, making mechanism preference often the deciding factor rather than practical considerations.
Making Your Choice: Expert Guidance Available
Both Wegovy and Mounjaro are available from EverydayMeds, positioning us uniquely to provide unbiased guidance based solely on your clinical suitability rather than product availability constraints. Your prescriber consultation considers factors including previous weight loss attempts, current medications, medical conditions, lifestyle factors, and personal preferences regarding injection frequency and storage requirements. We recommend discussing both options openly during your clinical assessment, as prescriber experience with your individual circumstances often reveals the optimal choice. New customers benefit from code FIRST40, whilst returning patients use DOSE25 for continued value across either treatment pathway. Our clinical team remains available throughout your journey for dose adjustments, side effect management, and treatment optimisation. Start your comparison today at https://everydaymeds.co.uk/collections/weight-loss and discover which prescription-only medicine aligns with your weight management goals under expert medical supervision.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
